Market Currents
Celsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a...
-
Wednesday, June 20, 2012, 8:32 AM ETCelsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a $1B cancer therapy with its ThermoDox treatment for liver cancer. CLSN, with a market cap of only ~$73M and just 16 employees, aims to place an old cancer drug into a new delivery method and adding heat in a recipe for success that can address a large unmet need in cancer.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 4 comments:
We'll see .....
Long CLSN
dave